S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end

NeuroPace (NPCE) Stock Forecast & Price Target

$13.98
-0.02 (-0.14%)
(As of 04/19/2024 ET)

NeuroPace Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$15.67
12.06% Upside
High Forecast$22.00
Average Forecast$15.67
Low Forecast$9.00
TypeCurrent Forecast
4/21/23 to 4/20/24
1 Month Ago
3/22/23 to 3/21/24
3 Months Ago
1/21/23 to 1/21/24
1 Year Ago
4/21/22 to 4/21/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$15.67$15.67$10.00$7.25
Predicted Upside12.06% Upside32.64% Upside18.74% Upside64.96% Upside
Get NeuroPace Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.

NPCE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NPCE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

NeuroPace Stock vs. The Competition

TypeNeuroPaceMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside12.06% Upside1,020.83% Upside11.92% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/14/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00+49.48%
3/6/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$9.00 ➝ $13.00+1.25%
3/6/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Osborn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$16.00 ➝ $18.00+40.19%
1/30/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/30/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$22.00+49.15%
12/27/2023Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$12.00+21.95%
11/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$6.00 ➝ $9.00+24.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:34 PM ET.

NPCE Price Target - Frequently Asked Questions

What is NeuroPace's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for NeuroPace stock is Moderate Buy based on the current 1 hold rating and 6 buy ratings for NPCE. The average twelve-month price prediction for NeuroPace is $15.67 with a high price target of $22.00 and a low price target of $9.00. Learn more on NPCE's analyst rating history.

Do Wall Street analysts like NeuroPace more than its competitors?

Analysts like NeuroPace more than other Medical companies. The consensus rating score for NeuroPace is 2.86 while the average consensus rating score for medical companies is 2.68. Learn more on how NPCE compares to other companies.

Is NeuroPace being upgraded by Wall Street analysts?

Over the previous 90 days, NeuroPace's stock had 1 upgrade by analysts.

Does NeuroPace's stock price have much upside?

According to analysts, NeuroPace's stock has a predicted upside of 32.64% based on their 12-month stock forecasts.

What analysts cover NeuroPace?

NeuroPace has been rated by Cantor Fitzgerald, Leerink Partnrs, Morgan Stanley, SVB Leerink, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:NPCE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners